Neuronal Signaling and MEK Signaling Pathway rosuvastatin in myocardial infarction

As reported elsewhere, after a median comply with up of 1.9 many years, MEK Signaling Pathway rosuvastatin use was related with a 54% reduction in myocardial infarction, a 48% reduction in stroke, a 46% reduction in revascularization, a 43% reduction in venous thromboembolism, and a 20% reduction in complete mortality.